JP2015078201A5 - - Google Patents

Download PDF

Info

Publication number
JP2015078201A5
JP2015078201A5 JP2014233012A JP2014233012A JP2015078201A5 JP 2015078201 A5 JP2015078201 A5 JP 2015078201A5 JP 2014233012 A JP2014233012 A JP 2014233012A JP 2014233012 A JP2014233012 A JP 2014233012A JP 2015078201 A5 JP2015078201 A5 JP 2015078201A5
Authority
JP
Japan
Prior art keywords
solid pharmaceutical
group
acid
pharmaceutical composition
atom
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014233012A
Other languages
English (en)
Japanese (ja)
Other versions
JP6391436B2 (ja
JP2015078201A (ja
Filing date
Publication date
Application filed filed Critical
Priority to JP2014233012A priority Critical patent/JP6391436B2/ja
Priority claimed from JP2014233012A external-priority patent/JP6391436B2/ja
Publication of JP2015078201A publication Critical patent/JP2015078201A/ja
Publication of JP2015078201A5 publication Critical patent/JP2015078201A5/ja
Application granted granted Critical
Publication of JP6391436B2 publication Critical patent/JP6391436B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014233012A 2013-04-25 2014-11-17 固形医薬組成物 Active JP6391436B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2014233012A JP6391436B2 (ja) 2013-04-25 2014-11-17 固形医薬組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2013092171 2013-04-25
JP2013092171 2013-04-25
JP2014233012A JP6391436B2 (ja) 2013-04-25 2014-11-17 固形医薬組成物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2014541237A Division JP5651812B1 (ja) 2013-04-25 2014-04-24 固形医薬組成物

Publications (3)

Publication Number Publication Date
JP2015078201A JP2015078201A (ja) 2015-04-23
JP2015078201A5 true JP2015078201A5 (enExample) 2017-06-15
JP6391436B2 JP6391436B2 (ja) 2018-09-19

Family

ID=51791434

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014541237A Active JP5651812B1 (ja) 2013-04-25 2014-04-24 固形医薬組成物
JP2014233012A Active JP6391436B2 (ja) 2013-04-25 2014-11-17 固形医薬組成物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2014541237A Active JP5651812B1 (ja) 2013-04-25 2014-04-24 固形医薬組成物

Country Status (7)

Country Link
US (1) US9603804B2 (enExample)
EP (1) EP2990038B1 (enExample)
JP (2) JP5651812B1 (enExample)
CN (1) CN105338982B (enExample)
CA (1) CA2910112C (enExample)
ES (1) ES2768651T3 (enExample)
WO (1) WO2014174846A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014174847A1 (ja) 2013-04-25 2014-10-30 杏林製薬株式会社 固形医薬組成物
WO2016063542A1 (ja) * 2014-10-23 2016-04-28 杏林製薬株式会社 固形医薬組成物
US20170246160A1 (en) * 2014-10-23 2017-08-31 Kyorin Pharmaceutical Co., Ltd. Solid pharmaceutical composition
WO2016195014A1 (ja) * 2015-06-02 2016-12-08 杏林製薬株式会社 水性液剤
JP6031217B1 (ja) * 2015-06-02 2016-11-24 杏林製薬株式会社 水性液剤
US10406149B2 (en) 2015-06-02 2019-09-10 Kyorin Pharmaceutical Co., Ltd. Aqueous liquid formulation
JP6675396B2 (ja) * 2015-06-02 2020-04-01 杏林製薬株式会社 水性液剤
JP6031216B1 (ja) * 2015-06-02 2016-11-24 杏林製薬株式会社 水性液剤
JP2021519334A (ja) 2018-03-26 2021-08-10 クリア クリーク バイオ, インコーポレイテッド ジヒドロオロト酸デヒドロゲナーゼを阻害するための組成物および方法
US20210300873A1 (en) 2020-03-20 2021-09-30 Clear Creek Bio, Inc. Stable polymorphic compositions of brequinar sodium and methods of use and manufacture thereof
JP2023518419A (ja) * 2020-03-20 2023-05-01 クリア クリーク バイオ, インコーポレイテッド ブレキナルナトリウムの安定した多形性組成物ならびにその使用および製造方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8524001D0 (en) 1985-09-30 1985-11-06 Glaxo Group Ltd Pharmaceutical composition
ZA87279B (en) 1986-01-17 1987-09-30 Chugai Pharmaceutical Co Ltd Method for production of stable nicorandil preparation
KR940000232B1 (ko) 1986-01-17 1994-01-12 쥬우가이세이야꾸 가부시끼가이샤 니코란딜 제제의 안정화 방법
JP2512302B2 (ja) 1986-03-19 1996-07-03 中外製薬株式会社 ニコランジル安定化製剤の製造方法
KR910700043A (ko) 1988-12-28 1991-03-13 우에하라 아끼라 타정시에 있어서 응력분산 방법
JP2682353B2 (ja) 1991-11-20 1997-11-26 武田薬品工業株式会社 経口用医薬組成物およびその製造法
TW284688B (enExample) 1991-11-20 1996-09-01 Takeda Pharm Industry Co Ltd
JP2006111639A (ja) 1993-10-21 2006-04-27 Takeda Chem Ind Ltd 医薬用錠剤
JPH08175996A (ja) 1994-12-22 1996-07-09 Taiyo Yakuhin Kogyo Kk ニコランジル安定化固形製剤の製法
JP3119801B2 (ja) 1995-09-28 2000-12-25 武田薬品工業株式会社 ビタミン含有組成物の安定化方法
JPH10245335A (ja) 1997-02-28 1998-09-14 Dainippon Pharmaceut Co Ltd 圧力に不安定な薬物の打錠方法及びそれに用いられる湿潤顆粒
ATE232728T1 (de) 1998-03-03 2003-03-15 Dae Woong Pharma Feuchtigkeitsstabile cefuroxim axetil enthaltende pharmazeutische zusammenstellungen
AT413647B (de) 1998-11-26 2006-04-15 Sandoz Ag Verwendung eines copolymerisats aus 1-vinyl-2-pyrrolidon und vinylacetat zur herstellung von cefuroximaxetil-hältigen tabletten
DE10048510A1 (de) 2000-09-29 2002-05-16 Fresenius Kabi De Gmbh Lagerstabile Infusionslösung des Ciprofloxacins mit verringertem Säuregehalt
ES2248521T3 (es) 2001-02-27 2006-03-16 Ranbaxy Laboratories, Ltd. Composicion farmaceutica oral de cefpodoxima proxetilo.
US7219132B2 (en) 2001-03-30 2007-05-15 Space Systems/Loral Dynamic resource allocation architecture for differentiated services over broadband communication networks
BR0308643A (pt) 2002-03-18 2005-02-09 Kyorin Seiyaku Kk Composto do derivado do ácido piridobenzoxazina carboxìlico e agente antibacteriano contendo o mesmo
ATE382338T1 (de) 2003-03-19 2008-01-15 Jordanian Pharmaceutical Mfg Nicht-hygroskopische pharmazeutische zusammensetzungen die nicht hydratisierte quinolon-carbonsäure enthalten
JP4639149B2 (ja) 2003-09-10 2011-02-23 杏林製薬株式会社 7−(4−置換−3−シクロプロピルアミノメチル−1−ピロリジニル)キノロンカルボン酸誘導体
EP1764102A4 (en) 2004-07-02 2010-08-25 Daiichi Seiyaku Co MEDICINAL COMPOSITION CONTAINING QUINOLONE
ES2322175T3 (es) 2004-09-17 2009-06-17 EISAI R&D MANAGEMENT CO., LTD. Composicion medicinal con estabilidad mejorada y gelificacion reducida.
EP1825866A4 (en) 2004-12-03 2008-03-12 Takeda Pharmaceutical SOLID PREPARATION
AR052559A1 (es) 2005-01-21 2007-03-21 Astex Therapeutics Ltd Derivados de pirazol para inhibir cdk's y gsk's
EP1843754B1 (en) 2005-01-26 2011-08-03 LEK Pharmaceuticals d.d. New pharmaceutical composition containing candesartan cilexetil as lipophilic crystalline substance
JP2006298811A (ja) 2005-04-20 2006-11-02 Taiyo Yakuhin Kogyo Kk ゲル化抑制製剤の設計
SA112330992B1 (ar) * 2011-11-10 2015-09-13 كيورين فارماسوتيكال كو.، ليمتد صورة متبلرة من 7-{(s4، s3)-3-[(سيكلو بروبيل أمينو) ميثيل]-4-فلورو بيروليدين-1-يل}-6-فلورو-1-(2-فلورو إيثيل)- 8-ميثوكسي-4-أوكسو-1، 4-داي هيدرو كينولين-3- حمض كربوكسيلي
JP6062422B2 (ja) * 2012-03-29 2017-01-18 杏林製薬株式会社 カプセル製剤
JP6050322B2 (ja) * 2012-03-29 2016-12-21 杏林製薬株式会社 カプセル製剤
WO2014174847A1 (ja) 2013-04-25 2014-10-30 杏林製薬株式会社 固形医薬組成物

Similar Documents

Publication Publication Date Title
JP2015078201A5 (enExample)
SA517390583B1 (ar) مشتقات حمض أميني جديدة، عملية لتحضيرها وتركيبات صيدلية تحتوي عليها
WO2017205536A3 (en) Heterocyclic inhibitors of cbp/ep300 and their use in the treatment of cancer
JP2015110646A5 (enExample)
JP2018531941A5 (enExample)
CA2983453A1 (en) Naphthyridine compounds as jak kinase inhibitors
EA201691590A1 (ru) Бензимидазол-2-амины в качестве ингибиторов midhi
TN2016000581A1 (en) Heteroaryl compounds useful as inhibitors of sumo activating enzyme
CN108026053A8 (zh) 作为mIDH1抑制剂的稠合的咪唑类化合物
MY160785A (en) Manufacturing process for pyrimidine derivatives
SG10201806565SA (en) Heterocyclic carboxylic acids as activators of soluble guanylate cyclase
ZA201805185B (en) Tlr7 agonist maleate salt, crystalline forms c, d and e thereof, preparation methods and uses of maleate salt and crystalline forms
MX2021006790A (es) Formulacion de tableta para compuestos activos de peptido relacionado con el gen de calcitonina.
EA201691136A1 (ru) Производное на основе 1,2-нафтохинона и способ его получения
HRP20241103T1 (hr) 2,4-di-(skupina koja sadrži dušik)-supstituirani pirimidinski spoj i postupak pripreme i njegova upotreba
SA519401322B1 (ar) مركبات أريل كربوكساميد غير متجانسة كمثطبات لكيناز بروتين سيرين/ ثريونين متداخل مع المستقبل 2
MX2016001096A (es) Sales de dasatinib en forma amorfa.
EA201691538A1 (ru) Способ получения солей вортиоксетина
JP2017501141A5 (enExample)
CN110891950A (zh) 一种三嗪化合物及其药学上可接受的盐
MX379859B (es) Compuestos de indolinona y su uso en el tratamiento de enfermedades fibróticas.
MX2020004981A (es) Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3.
MX2016001095A (es) Sales de dasatinib en forma cristalina.
PH12019500822A1 (en) Crystalline forms of eravacycline
EA201892020A1 (ru) Индольные производные и их применение в качестве ингибиторов протеинкиназы